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The Clozapine Prescription Rates and Current Clinical Practice
Clozapine is the only registered treatment for therapy-resistant schizophrenia (meaning, after
treatment with two other antipsychotics failed or were not tolerated), psychosis in Parkinson’s
disease, and, in the United States, for suicidality. Off-label, clozapine is prescribed for therapy-
resistant disorders, especially therapy-resistant bipolar, borderline personality, violent behavior,
or self-harm in patients with psychosis, aggressive behavior, or addiction to cannabis in psychotic
disorder and in the animal model.
Despite the good evidence of efficacy [1] and now robust evidence that clozapine use may be
associated with lowered mortality compared to other antipsychotics [2], the use of clozapine
remains suboptimal in most countries, both within and outside Europe [3].
Low prescription rates not only result in poor treatment for schizophrenia, an unintended
consequence is that trainees and consultants in psychiatry have less experience and, therefore,
lack confidence in initiating and maintaining the clozapine therapy. In a major survey of UK
practice, it was found that almost one third of senior consultants have not prescribed the
clozapine, for more than a year. It appears that a vicious cycle sets in; because clozapine is less
prescribed, doctors have less exposure and confidence in prescribing it which in turn results in
even lesser exposure tomanaging the drug and its side effects. Not surprisingly, this promotes the
aura for clozapine as a dangerous drug, which results in prescribers’ fear.
Educational Interventions for Improving the Clinical Practice in Treatment-Resistant
Schizophrenia
Systematic reviews on barriers to effective clozapine use identify lack of adequate training in
initiating or maintaining clozapine use as a major barrier [4]. Inadequate knowledge or expe-
rience in clozapine use, fear of side effects, lack of knowledge about clozapine side effects, lack of
adherence with guidance and difficulty identifying suitable patients, and unclear guidance
regarding clozapine monitoring were identified as a major contributor to poor prescribing for
clozapine by majority of participants in these studies.
Many psychiatry training programs do not include specific aspects of clozapine initiation and
monitoring in the syllabi. In the United Kingdom, for example, the Royal College of Psychiatrists,
the core training in psychiatry only mentions treatment-resistant schizophrenia management as a
learning objective, without any mention of clozapine. In the higher training in general adult
psychiatry, there is only one learning objective (intended learning outcome [ILO]) related to
treatment of severe mental illness [5].Mostly, the textbooks in psychiatry cover the risks associated
with clozapine use and monitoring, but the evidence related to beneficial effects of clozapine and
proactive approach in managing side effects is rarely covered. While the emphasis on monitoring
clozapine use is understandable, this merely reinforces the clozapine as a dangerous drug.
There is some evidence that educational interventions improve the rates and quality of
clozapine prescriptions. These educational interventions include Dutch [6], the United States
[7], Australia [8], and New Zealand [9] examples. The content of these educational interventions
varies but essentially covers following aspects: increased training in clozapine in identifying
suitable patients for clozapine, education in side effects management, developing and imple-
menting standardized protocols for medical review, supporting documentation and adverse
event management, shared decision-making, and training in use of point care devices.
However laudable and effective these interventions are, they remain isolated efforts, which are
not supported by educational institutions. The content and methodology of these training
programs are also not standardized.
A Mandatory Training and Certification Program for Clozapine
We propose a mandatory training program that requires a certification in core competencies
for initiating and maintaining clozapine in psychiatry residence programs. Clozapine is not a
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clozapine prescription and management. The requirements for
mandatory monitoring, potential benefits from effective use and
wide array of side effects and the expertise needed for their
management requires a mandatory program of training and
certification in clozapine use.
This will ensure all trainees getting uniform training in essen-
tial clozapine prescribing. This will also provide confidence to
service users. The syllabus, ILOs, and the assessment methods for
such a training program can be constructed after consultations
with the experts in the field. Number of skills and competencies in
medicine and psychiatry require certain standards to be met.
In psychiatry, for example, minimum standards of training are
required for practitioners of electroconvulsive therapy (ECT). The
good practice guide to ECT training in the United Kingdom requires
that junior trainees should be able to administer ECT without direct
supervision, prepare patients for ECT, and explain to patients and
relatives the facts about ECT, its indications, and broad place within
psychiatric treatment. They ought to be able to monitor a patient’s
mental state and cognitive functioning during a course of ECT. It is
further specified that the higher trainees ought to maintain this
capability until the end of year 6. The good practice guide also
elaborates the details of competencies in theory and practice of ECT
that must be met in order for a practitioner to administer ECT [10].
We suggest that a similar training program for clozapine initi-
ation and maintaining must become part of basic and higher
psychiatric training programs. Based on our research in this field
and delivering workshops for effective clozapine prescriptions in
the EPA congress and other forums, we suggest following broad
areas covered in such a training program.
Clozapine prescription
Indications—The training must include both registered and off-
label indications of clozapine use. The evidence for efficacy and
effectiveness, strategies for clozapine initiation, titration, and in
maintenance therapy, audit, andmonitoring in clinical practice will
also be included in training programme.
Monitoring and Safety Strategies and Procedures
Side effects
The incidence and ways of early detection of the four main rare, but
potential lethal, side effects: agranulocytosis, diabetic ketoacidosis,
ileus, and myocarditis. The incidence and detection of common
harmless but bothersome common side effects, such as sialorrhea
and constipation. The treatment strategies for these side effects.
Interactions
The liver cytochrome system (CYP) inducers, such as carbamaze-
pine and the polyaromatic compounds of tobacco smoke, and with
CYP inhibitors, such as caffeine (in coffee, cola, or many energy
drinks), psychiatric, and nonpsychiatric (co-)medication.
POCT
The availability, possibilities, and use of point-of-care devices.
Involving service users in shared decision-making
This should include principles of shared decision-making (SDM) in
initiating and maintaining clozapine treatment, support for patients
and families, decision aid tools to assist SDM, capacity and consent
for starting clozapine use, and internet-based educational programs
to provide information for consumers, family members, and clini-
cians, involving service users in monitoring for safety.
The assessmentmethods for these training programsmay include
Multiple Choice Questions (MCQs), patient scenarios, and objective
structured clinical examination for service users involvement. The
syllabus, learning methods, and evaluation of learning outcomes for
such a program can be developed in consultation with psychiatry
residency programs across Europe in collaboration with EPA.
The ILO for such a program can be developed for core psychi-
atry training and higher psychiatric programs in consultation with
the psychiatric training program in different countries. The essen-
tial elements of such programs can be developed by the EPA
Committee on Education.
Conclusion
A structural approach of professionals’ barriers to clozapine pre-
scription requires adequate and sufficient education of both psy-
chiatrists and trainees on all aspects of clozapine.
The logical consequence is that education and training in the use
of clozapine must become a mandatory requirement of all psychi-
atry residence and Continuing Professional Development (CPD)
programs, similar to the certification for ECT.
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